Generics Cos. Prevail In AstraZeneca's Crestor Suit

Law360, New York (December 16, 2010, 3:47 PM EST) -- A federal judge has ruled that AstraZeneca Pharmaceuticals LP can not use two method patents to block generic versions of its blockbuster cholesterol drug Crestor, a decision that could shorten the time before cheaper versions of the medication hit the market.

Judge Robert B. Kugler of the U.S. District Court for the District of Delaware issued the ruling Wednesday, saying AstraZeneca cannot rely on the two method patents because the generic-drug companies sought to market their versions of the drug for uses not covered by those...
To view the full article, register now.